Tempest Therapeutics (NASDAQ:TPST) Stock Price Down 1.6% – Should You Sell?

Tempest Therapeutics, Inc. (NASDAQ:TPST)’s share price was down 1.6% during trading on Thursday . The company traded as low as $1.24 and last traded at $1.25. Approximately 41,415 shares changed hands during mid-day trading, a decline of 65% from the average daily volume of 118,351 shares. The stock had previously closed at $1.27.

Wall Street Analysts Forecast Growth

A number of analysts have commented on TPST shares. Wall Street Zen lowered Tempest Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Zacks Research lowered Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Reduce”.

Tempest Therapeutics Stock Up 0.8%

The company has a market cap of $18.66 million, a P/E ratio of -0.21 and a beta of -1.85. The company has a fifty day moving average of $1.74 and a 200 day moving average of $2.32.

Tempest Therapeutics (NASDAQ:TPST) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($0.28) by ($2.25). As a group, research analysts forecast that Tempest Therapeutics, Inc. will post -1.34 EPS for the current year.

Insider Activity at Tempest Therapeutics

In other news, CEO Matthew Angel acquired 231,482 shares of the business’s stock in a transaction that occurred on Tuesday, March 24th. The stock was bought at an average price of $2.16 per share, with a total value of $500,001.12. Following the completion of the acquisition, the chief executive officer directly owned 231,482 shares of the company’s stock, valued at approximately $500,001.12. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.28% of the stock is owned by insiders.

Institutional Trading of Tempest Therapeutics

Several large investors have recently modified their holdings of the company. Dimensional Fund Advisors LP bought a new stake in shares of Tempest Therapeutics in the fourth quarter worth $33,000. Vanguard Group Inc. grew its holdings in Tempest Therapeutics by 20.8% during the third quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after purchasing an additional 27,952 shares during the period. Finally, Sabby Management LLC bought a new stake in Tempest Therapeutics during the fourth quarter valued at about $513,000. Institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.